BioCryst Pharmaceuticals Inc (BCRX) — Cash Flow Reinvestment Rate

Latest as of December 2025: 0.28x

BioCryst Pharmaceuticals Inc (BCRX) has a Cash Flow Reinvestment Rate of 0.28x as of December 2025, reinvesting $77.31 Million (capex $802.00K plus investments $-76.50 Million) from operating cash flow of $276.04 Million. See BioCryst Pharmaceuticals Inc (BCRX) free cash flow to measure how efficiently the company converts operating cash flow to free cash.

Reinvestment Rate

0.28x

(Capex + Investments) / Operating CF

Total Reinvested

$77.31 Million

Capex + Investments

Operating Cash Flow

$276.04 Million

USD

Capital Expenditures

$802.00K

USD

BioCryst Pharmaceuticals Inc Cash Flow Reinvestment Rate (2025–2025)

Historical reinvestment intensity for BioCryst Pharmaceuticals Inc across 1 annual periods. For the full cash flow conversion analysis, see BCRX operating cash flow.

Annual Cash Flow Reinvestment Rate for BioCryst Pharmaceuticals Inc (2025–2025)

Year-by-year capital reinvestment analysis for BioCryst Pharmaceuticals Inc. See BioCryst Pharmaceuticals Inc (BCRX) flexibility index to measure the company's free cash flow as a share of total liabilities.

Year	Reinvestment Rate	Total Reinvested (USD)	Operating CF	Capex	YoY Change
2025	0.02x	$8.06 Million	$329.88 Million	$2.47 Million	—

Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow